Vulvar Cancer Pipeline Insight 2024, with Key Focus on TAK-242, Vudalimab, PEN-866, Artesunate, IRX-2, ISA101, VicOryx, PRV111, PRGN-2009, ABI-2280 and CUE-101
April 16, 2024 12:46 ET
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Vulvar Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive...